Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.

Hdl Handle:
http://hdl.handle.net/10147/324301
Title:
Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.
Authors:
Lowery, Aoife J; Walsh, Siun; McDermott, Enda W; Prichard, Ruth S
Affiliation:
Department of Surgery, St. Vincent's University Hospital, Dublin, Ireland.
Citation:
Lowery AJ et al. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. 2013, 18 (4):391-407 Oncologist
Journal:
The oncologist
Issue Date:
2013
URI:
http://hdl.handle.net/10147/324301
DOI:
10.1634/theoncologist.2012-0410
PubMed ID:
23576482
Abstract:
Pheochromocytomas (PCCs) and paragangliomas (PGLs) are rare catecholamine-secreting tumors derived from chromaffin cells originating in the neural crest. These tumors represent a significant diagnostic and therapeutic challenge because the diagnosis of malignancy is frequently made in retrospect by the development of metastatic or recurrent disease. Complete surgical resection offers the only potential for cure; however, recurrence can occur even after apparently successful resection of the primary tumor. The prognosis for malignant disease is poor because traditional treatment modalities have been limited. The last decade has witnessed exciting discoveries in the study of PCCs and PGLs; advances in molecular genetics have uncovered hereditary and germline mutations of at least 10 genes that contribute to the development of these tumors, and increasing knowledge of genotype-phenotype interactions has facilitated more accurate determination of malignant potential. Elucidating the molecular mechanisms responsible for malignant transformation in these tumors has opened avenues of investigation into targeted therapeutics that show promising results. There have also been significant advances in functional and radiological imaging and in the surgical approach to adrenalectomy, which remains the mainstay of treatment for PCC. In this review, we discuss the currently available diagnostic and therapeutic options for patients with malignant PCCs and PGLs and detail the molecular rationale and clinical evidence for novel and emerging diagnostic and therapeutic strategies.
Item Type:
Article
Language:
en
Keywords:
CANCER; THERAPY
Local subject classification:
NEOPLASMS, ADRENAL GLAND
MeSH:
Adrenal Gland Neoplasms; Adrenalectomy; Diagnostic Imaging; Humans; MicroRNAs; Mutation; Neoplasm Recurrence, Local; Paraganglioma; Pheochromocytoma; Prognosis
ISSN:
1549-490X

Full metadata record

DC FieldValue Language
dc.contributor.authorLowery, Aoife Jen_GB
dc.contributor.authorWalsh, Siunen_GB
dc.contributor.authorMcDermott, Enda Wen_GB
dc.contributor.authorPrichard, Ruth Sen_GB
dc.date.accessioned2014-08-06T10:46:28Z-
dc.date.available2014-08-06T10:46:28Z-
dc.date.issued2013-
dc.identifier.citationLowery AJ et al. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas. 2013, 18 (4):391-407 Oncologisten_GB
dc.identifier.issn1549-490X-
dc.identifier.pmid23576482-
dc.identifier.doi10.1634/theoncologist.2012-0410-
dc.identifier.urihttp://hdl.handle.net/10147/324301-
dc.description.abstractPheochromocytomas (PCCs) and paragangliomas (PGLs) are rare catecholamine-secreting tumors derived from chromaffin cells originating in the neural crest. These tumors represent a significant diagnostic and therapeutic challenge because the diagnosis of malignancy is frequently made in retrospect by the development of metastatic or recurrent disease. Complete surgical resection offers the only potential for cure; however, recurrence can occur even after apparently successful resection of the primary tumor. The prognosis for malignant disease is poor because traditional treatment modalities have been limited. The last decade has witnessed exciting discoveries in the study of PCCs and PGLs; advances in molecular genetics have uncovered hereditary and germline mutations of at least 10 genes that contribute to the development of these tumors, and increasing knowledge of genotype-phenotype interactions has facilitated more accurate determination of malignant potential. Elucidating the molecular mechanisms responsible for malignant transformation in these tumors has opened avenues of investigation into targeted therapeutics that show promising results. There have also been significant advances in functional and radiological imaging and in the surgical approach to adrenalectomy, which remains the mainstay of treatment for PCC. In this review, we discuss the currently available diagnostic and therapeutic options for patients with malignant PCCs and PGLs and detail the molecular rationale and clinical evidence for novel and emerging diagnostic and therapeutic strategies.en_GB
dc.language.isoenen
dc.rightsArchived with thanks to The oncologisten_GB
dc.subjectCANCERen_GB
dc.subjectTHERAPYen_GB
dc.subject.meshAdrenal Gland Neoplasms-
dc.subject.meshAdrenalectomy-
dc.subject.meshDiagnostic Imaging-
dc.subject.meshHumans-
dc.subject.meshMicroRNAs-
dc.subject.meshMutation-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshParaganglioma-
dc.subject.meshPheochromocytoma-
dc.subject.meshPrognosis-
dc.subject.otherNEOPLASMS, ADRENAL GLANDen_GB
dc.titleMolecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.en_GB
dc.typeArticleen
dc.contributor.departmentDepartment of Surgery, St. Vincent's University Hospital, Dublin, Ireland.en_GB
dc.identifier.journalThe oncologisten_GB
dc.description.fundingNo fundingen
dc.description.provinceLeinsteren
dc.description.peer-reviewpeer-reviewen

Related articles on PubMed

All Items in Lenus, The Irish Health Repository are protected by copyright, with all rights reserved, unless otherwise indicated.